DESCRIPTION
COMPOSITION OF SOLIFENACIN OR SALT THEREOF FOR USE IN SOLID
FORMULATION
Technical Field
The present invention relates to a composition of
solifenacin or a salt thereof for use in solid formulation,
the composition containing the crystal of solifenacin or a salt
thereof at an amorphous content within a range with no influence
on the stability of the resulting product, as well as a method
for producing the same. Additionally, the invention relates
to a pharmaceutical composition containing solifenacin or a
salt thereof and an inhibitor of amorphous preparation.
Background Art
Solifenacin is represented by the following formula (I) :
[Chemical formula 1]


and is chemically called (1R, 3'R)-3'-quinuclidinyl
1-phenyl-1, 2, 3, 4-tetrahydro-2-isoquinoline carboxylate.
It is reported that a series of quinuclidine derivatives
including solifenacin or salts thereof have an excellent
selective antagonistic action against muscarine M3 receptors
and are useful as prophylactic or therapeutic agents of urinary
diseases such as nervous pollakiuria, neurogenic bladder,
nocturnal enuresis, unstable bladder, bladder contracture,
and chronic cystitis as well as respiratory diseases such as
chronic occlusive lung diseases, chronic bronchitis, asthma
and rhinitis (see patent reference 1).
A manufacturing process of solifenacin hydrochloride is
described in Example 8 in the patent reference 1, wherein the
crystal resulting from crystallization in a mixture solvent
of acetonitrile and diethyl ether has a melting point of 212
to 214°C and has a specific rotation ([α]25D of 98.1 (c= 1.00,
EtOH}.
However, the patent reference 1 includes no description
or suggestion about significant degradation over time of
amorphous solifenacin or an amorphous salt thereof or
solifenacin succinate as an active pharmaceutical ingredient
in a formulation when solifenacin succinate product is
formulated by a general pharmaceutical manufacturing process.
Non-patent reference 1 publicly issued by the Japanese
Ministry of Health, Labor and Welfare in June, 2003 includes

the description about the specification of drug products,
namely the concept about degradation products (impurities) in
new drug products as observed at stability tests. According
to the reference, the threshold of a degradation products
requiring safety qualification in a drug product is a lower
one of either 1.0 % as the percentage of the degradation product
contained in a drug substance or 50 μg as the total daily intake
of the degradation product, when the amount of the drug
substance to be administered per day is less than 10 mg. When
the amount of the drug substance to be administered per day
is 10 mg or more to 100 mg or less, the threshold of a degradation
product requiring safety qualification in a drug products is
a lower one of either 0.5 % as the percentage of the degradation
product contained in a drug substance or 2 00 μg as the total
daily intake of the degradation product. Therefore, the
specification of a degradation product as can be determined
with no requirement of any safety qualification of the
degradation product is generally 1.0 % or less as the percentage
of the degradation product contained in a drug substance, when
the formulation is for example at a 5-mg content of the drug
substance. When the formulation is for example at a 10-mg
content of the drug substance, the percentage of the
degradation product contained in the drug substance is 0.5 %
or less.
Solifenacin formulations, currently planned in a market

on the basis of clinical test results,, are 2.5-mg, 5-mg, and
10-mg tablets. For these formulations to have the stability
described in the non-patent reference 1, it was considered that
the amount of the main degradation product (abbreviated as Fl
hereinafter) of solifenacin succinate to the total amount of
solifenacin succinate and degradation products thereof should
be set at 0.5 % or less and that the amount should be controlled
to 0.4 % or less, considering lot-to-lot variation and test
errors.
Patent reference 1: Specification of EP 801 067
Non-patent reference 1: Notification No. 0624001 issued
by Japanese Committee of Pharmaceutical Affairs, "Revision of
Guideline about Impurities in New Drug Products containing
Novel Active Pharmaceutical Ingredients"
Disclosure of the Invention
Problems that the Invention is to Solve
The present inventors granulated solifenacin succinate
by the fluidized bed granulation process under general
conditions for persons skilled in the art and manufactured the
tablets for developing solifenacin succinate as an excellent
therapeutic agent of pollakiuria and incontinence of urine.
Then, the inventors carried out a preliminary stability test
of the resulting tablet over 6 months at an acceleration test
(at 40°C and 75% RH (relative humidity) using bottle-sealing

conditions) as one of general stability tests. Consequently,
the inventors observed the decrease in the residual ratio of
solifenacin succinate, so that the amount of the generated F1
to the total amount of solifenacin succinate and degradation
products thereof exceeded 0.4 % (see Table 2 below in detail) .
The inventors understood that it was difficult to obtain a
formulation thereof with pharmaceutically sufficient
stability by such general pharmaceutical manufacturing
process.
In providing a solid formulation of solifenacin or a salt
thereof as an excellent therapeutic agent of pollakiuria and
incontinence of urine, in other words, the development of a
solid formulation of solifenacin or a salt thereof stable over
time has been desired strongly, which can inhibit the amount
of Fl generated to the total amount of solifenacin or a salt
thereof and degradation products thereof to 0.4 % or less.
Means for Solving the Problems
The degradation of a drug substance in a formulation
generally involves for example redox reaction, hydrolysis
reaction, racemization, photodegradation and polymeric
degradation. It has been described that these reactions have
a correlation with heat, oxygen, light, water and interactions
with other components. As described above, numerous causes
in relation with drug degradation should be considered so as

to obtain stable drug products. In such state of technical
level, the inventors made investigations about the
stabilization of solifenacin products. Unexpectedly, the
inventors elucidated that amorphous solifenacin succinate
generated during a manufacturing process of the drug products
was the main cause of the degradation of the active
pharmaceutical ingredient over time.
Additionally, the inventors found that the amorphous
content in the drug products could be inhibited by adjusting
the moisture content in a drug product during manufacturing
process when the drug products were prepared by the wet
granulation process using aqueous solutions of general binders
or by a heating and/or moisturizing process of the resulting
composition after the production manufacturing process. The
inventors found that a stable solid formulation of solifenacin
or a salt thereof wherein the degradation thereof over time
could be inhibited could be produced when the ratio of amorphous
solifenacin in crystalline and amorphous solifenacin was at
a given value or less.
Furthermore, the inventors found that a formulation of
solifenacin wherein the degradation of solifenacin over time
could be inhibited could be produced when polyethylene glycol
(Macrogol under another name; abbreviated as PEG hereinafter)
was used as a binder irrespective of the manufacturing process
thereof, although PEG itself was a substance to be used

generally for the purpose of preparing drugs into an amorphous
state. Thus, the invention has been achieved, other than the
stabilization process described above.
In other words, the invention relates to those described
below.
1. A composition of solifenacin or a salt thereof for use
in solid formulation, the composition containing the crystal
of solifenacin or a salt thereof, wherein the amorphous content
is within a range showing no influence on drug product
stability.
2. A composition of solifenacin or a salt thereof for use
in solid formulation, as described above in 1, wherein the
amorphous content is 77 % or less.
3. A composition for use in solid formulation, as described
above in 1 or 2, which is produced by a manufacturing process
including a step of blending solifenacin or a salt thereof with
excipients without using a solvent, followed by
compression-molding.
4. A composition for use in solid formulation, as described
above in 1 or 2, which is produced by a manufacturing process
including a step of adding a solvent to solifenacin or a salt
thereof, wherein the amount of solifenacin or a salt thereof
to be dissolved per 1 mL of the solvent is less than 0.1 mg.
5. A composition for use in solid formulation, as described
above in 4, wherein the solvent added to solifenacin or a salt

thereof is acetone or hexane or a mixture thereof.
6. A composition for use in solid formulation, as described
above in 1 or 2, which is produced by a manufacturing process
including a step of adding a solvent to prepare solifenacin
or a salt thereof into an amorphous state, wherein the amount
of solifenacin or a salt thereof to be dissolved per 1 mL of
the solvent is 10 mg or more.
7. A composition for use in solid formulation, as described
above in 6, wherein the solvent to prepare solifenacin or a
salt thereof into an amorphous state is water, methanol or
ethanol or a mixture thereof.
8. A composition for use in solid formulation as described
above in 1 through 7, which is produced by a manufacturing
process including a step of promoting the crystallization of
amorphous solifenacin or an amorphous salt thereof.
9. A mixture of solifenacin or a salt thereof, wherein the
mixture contains amorphous and crystalline solifenacin or an
amorphous and crystal salt thereof and wherein the amorphous
content of solifenacin or a salt thereof is within a range
showing no influence on product stability.
10. A pharmaceutical composition for use in solid
formulation, the composition containing crystalline and
amorphous solifenacin or a crystalline and amorphous salt
thereof, together with a inhibitor of amorphous preparation.
11. A pharmaceutical composition described above in 10,

wherein the inhibitor of amorphous preparation is a substance
showing ethylene oxide chain.
12. A pharmaceutical composition described above in 11,
wherein the substance having ethylene oxide chain is
polyethylene glycol.
When compressed according to a formulation in blend with
an additive, techniques are known, including a stabilization
technique of (E)-1-[4-(2-dimethylamino)ethoxy]phenyl-2-
(4-isopropylphenyl)-1-(4-phosphonooxy)phenyl-1-butene with
a property such that degradation products thereof increase in
an accelerating manner over time under influences such as
moisture contained in such additive, the increase in the
contact of the tablet inside with the additive via pressure
molding, and the reduction of the crystallinity via
pressurization and with an efficacy as a therapeutic agent of
breast cancer via moisture reduction (Chemical &
Pharmaceutical Bulletin, 42(12), 2582(1994)), and a
stabilization technique of a composition containing the
compound by the melt granulation manufacturing process
(JP-A-Hei 9-110698) for example a stabilization technique
(JP-A-Hei 10-007547) by a substantially anhydrous process of
manufacturing a solid formulation in a tablet form of anilide
compounds for use in multiple sclerosis, which involves much
difficulty in accurately administering the anilide compounds
as the principal component because compounds different from

the principal compound in the solid formulation are generated
at 6 to 9 % during storage.
However, these technical references never include any
description of solifenacin or a salt thereof with a structure
totally different from those of disclosed compounds and with
physicochemical or pharmacological properties totally,
different from those of disclosed compounds or never include
any description or suggestion about the problem of the
degradation of a solid formulation containing amorphous form
over time or about the stabilization thereof by adjusting the
amorphous content below the appropriate amount in the
resulting solid formulation.
The official gazette of JP-A-Hei-5-194218 discloses a
stabilization technique of nitrogen-containing hetero-ring
alkylphenyl derivatives with an anti-angiotensin II action,
of which the content reduction is accelerated via crystalline
deformation due to kneading during production course, and
pressure, abrasion, heat and the like imposed during
granulation or pressure molding, wherein the technique
includes a step of blending an oily substance with a low melting
point such as PEG in such alkylphenyl derivatives to stabilize
the resulting oral formulation, when the alkylphenyl
derivatives are formulated according to a formulation in blend
with other components. In this case, the stabilization
mechanism with the substance with a low melting point is via

the inhibition of the thermal degradation of the active
pharmaceutical ingredient by blending the oily substance with
a low melting point uniformly in the active pharmaceutical
ingredient. No description is included therein about the
contribution of the substance with a low melting point to the
crystallinity of the active pharmaceutical ingredient. The
mechanism is totally different from the stabilization
mechanism in accordance with the invention.
Additionally, International Journal of Pharmaceutics,
216(2001) 43-49 reports that in co-dissolving and
crystallizing lactose with PEG, the precipitated lactose
exists in a crystal state. Alternatively, International
Journal of Pharmaceutics, 127(1996) 261-272 and International
Journal of Pharmaceutics, 262(2003)125-137 report that in
co-dissolving and crystallizing a drug with PEG, the drug is
at an amorphous state. In case of co-dissolving and
crystallizing an active pharmaceutical ingredient with
polymer such as PEG, generally, the resulting active
pharmaceutical ingredient is frequently in an amorphous state,
although it depends on the properties of the active
pharmaceutical ingredient. Research works about blending for
the purpose of amorphous preparation via the solubilization
of slightly soluble drugs and the like have been known commonly.
All compounds disclosed in these technical references have
chemical structures totally different from the structure of

solifenacin. The references never include any description
about solifenacin or a salt thereof, with different
physicochemical and pharmacological properties or any
suggestion about a finding to establish the anticipation about
the crystallization or amorphous preparation of solifenacin
via the blending with PEG. Even about stabilization, the
references never describe or suggest the constitution such
that the degradation of the active pharmaceutical ingredient
over time can be inhibited by utilizing the crystallization
via polymers such as PEG.
The inventive composition is now described below in
detail.
The "salt of solifenacin" for use in accordance with the
invention includes acid addition salts of solifenacin with
mineral acids such as hydrochloric acid, hydrobromic acid,
hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid,
organic acids such as formic acid, acetic acid, propionic acid,
oxalic acid, malonic acid, succinic acid, fumaric acid, maleic
acid, lactic acid, malic acid, citric acid, tartaric acid,
carbonic acid, picric acid, methanesulfonic acid,
ethanesulfonic acid and glutamic acid, and quaternary ammonium
salts thereof, as described in the patent reference 1.
Specifically, solifenacin succinate is preferable in
providing a pharmaceutical product and also achieves the
stabilization effect greatly in accordance with the invention.

Thus, the succinate salt is particularly selected.
"Solifenacin or a salt thereof" for use in accordance
with the invention is readily available by the processes
described in the patent reference 1 or according to the
processes or by routine methods. The quantity of solifenacin
or a salt thereof to be blended in the composition for use in
solid formulation in accordance with the invention
satisfactorily contains an active quantity thereof per unit
dose formulation. The quantity is preferably at 0.001 % by
weight to 97 % by weight, more preferably at 0.05 % by weight
to 50 % by weight, still more preferably at 0.05 % by weight
to 20 % by weight, most preferably at 0.05 % by weight to 10 %
by weight. When the pharmaceutical composition of the
invention is a particle such as granule, the quantity of the
drug blended in the particle pharmaceutical composition is
appropriately selected, generally depending on the types of
the drug or the pharmaceutical use (indication) thereof. A
therapeutically active quantity thereof or a prophylactically
active quantity thereof is satisfactory, with no specific
limitation.
Additionally, the daily dose of solifenacin or a salt
thereof is preferably 0.01 mg to 100 mg, more preferably 0.5
mg to 50 mg, still more preferably 0.5 mg to 20 mg, most
preferably 0.5 mg to 10 mg.
The "crystal" or "crystalline substance" of solifenacin

or a salt thereof means a substance of solifenacin or a salt
thereof with the crystalline structure referred to in the
crystallography field as the term means. In accordance with
the invention, the crystal or crystalline means a substance
with less solifenacin degradation over time. The term crystal
or crystalline means a substance different from an amorphous
substance with significant solifenacin degradation over time
when the substance exists over the range with no influence on
drug product stability in a formulation.
In accordance with the invention, meanwhile, the term
"amorphous" solifenacin or a salt thereof or "amorphous
substance" of solifenacin or a salt thereof mean a substance
with a crystallographically amorphous structure. In
accordance with the invention, meanwhile, the term "amorphous
solifenacin or amorphous salt thereof" or "amorphous substance
of solifenacin or a salt thereof" means a substance with a
significant degradation of solifenacin when it exists over the
range with no influence on drug product stability and
additionally means a substance different from the "crystal"
or the "crystalline substance" with less solifenacin
degradation over time.
In accordance with the invention, additionally, the
"amorphous content" means the ratio of the amorphous substance
to the total of amorphous and crystalline solifenacin or an
amorphous and crystal salt thereof.

In accordance with the invention, the phrase "within a
range with no influence on drug product stability" means that
the product of solifenacin or a salt thereof is stable under
severe conditions during the distribution course of the
commercial product. Specifically, the quantity of the main
generated degradation product of solifenacin to the total of
solifenacin or a salt thereof and degradation products thereof
can be inhibited to 0.4 % or less at a preliminary stability
test using bottle-sealing conditions at 40°C and 75% RH for
6 months.
In accordance with the invention, therefore, the
specific amorphous content within a range with no influence
on product stability is 77 % or less, preferably 73 % or less,
still more preferably 71 % or less, most preferably 63 % or
less to the total of amorphous and crystalline solifenacin or
an amorphous and crystal salt thereof in case of measurement
by near infrared spectrometry. Furthermore, solifenacin or
a salt thereof with an initial amorphous content exceeding a
range with no influence on product stability immediately after
the production but progressing the crystallization over time
so that the amorphous content falls within a range with no
influence on product stability is also included within the
scope of the invention. Thus, the timing for the measurement
of the amorphous content is with no specific limitation.
Taking into account that the amorphous content is to certify

product stability during the distribution course, preferably,
the amorphous content is measured at the time of the start of
the distribution of the product or in an appropriate timing
thereafter.
The method for assessing the amorphous content of
solifenacin or a salt thereof in accordance with the invention
is generally any method for identifying the crystalline
structure of solifenacin or a salt thereof in the composition
but includes for example powder X ray diffraction method, DSC
method, solid NMR and near infrared spectrometry. For
measuring the crystalline structure of a drug at a lower content
in a mixture composition with other components, in particular,
the crystalline structure is preferably measured by solid NMR
or near infrared spectrometry. A method for measuring the
structure in a simpler way is near infrared spectrometry.
As the method for measuring the amorphous content of
solifenacin succinate, for example, a method by near infrared
spectrometry was used by measuring the spectrum with a Fourier
transform near infrared spectrometer (Vector 22/N, Bruker
Optik GmbH, Germany) (a measurement range; 10000 cm"1 to 4000
cm"1, resolution; 2 cm"1, scan number; 126) and secondary
derivation of the resulting spectrum (Savitzky-Gollay
convolution method) for analysis with a near infrared spectral
analysis software (for example, OPUS, Bruker Optik GmbH,
Germany). Prior to the spectral measurement of the tablet,

the spectra of products prepared by mixing together various
ratios of crystalline and amorphous solifenacin succinate
preliminarily prepared by spray-drying method of aqueous
solifenacin succinate solution are analyzed by regression
analysis by the partial least squares method, to prepare a
standard curve. Inserting the spectrum of the tablet on the
standard curve, the amorphous content of solifenacin succinate
can be determined.
As the method for measuring the amorphous content of
solifenacin succinate by solid NMR, for example, the spectrum
of the tablet is measured with a solid NMR apparatus (for
example CMX-300, manufactured by Chemagnetics, USA) (for
example, probe used; made of ceramics, 7.5 mm probe, contact
time; 9 msec, pulse repeat time; 38 sec, sample rotation number;
5 kHz) . The resulting spectrum is data-processed (for example,
index function window, broadening factor; 30 Hz, trapezoid
window; t1 = 0, t2 = 0, t3 = 0.5, t4 = 0.6). Furthermore,
crystalline and amorphous solifenacin succinate preliminarily
prepared by spray-drying method of aqueous solifenacin
succinate solution are mixed together at various ratios.
Using then lactose as an internal standard, the peak/height
ratio of crystalline solifenacin succinate is determined to
prepare a standard curve. Inserting the peak/height ratio of
crystalline solifenacin succinate resulting from the tablet
spectrum on the standard curve, the crystal content of

solifenacin succinate and the amorphous content can be
determined.
The "composition for use in solid formulation" in
accordance with the invention is any pharmaceutical
composition for use in solid formulation with no specific
limitation, wherein the degradation of solifenacin or a salt
thereof over time can be inhibited because the amorphous
content is within a range with no effect on product stability.
The term means oral and parenteral compositions such as tablets,
pills, powders, granules and capsules.
The phrase "mixture of solifenacin or a salt thereof
containing amorphous and crystalline solifenacin or an
amorphous and crystalline salt thereof, wherein the amorphous
content is within a range with no influence on product
stability" means a mixture of amorphous and crystalline
solifenacin or an amorphous and crystalline salt thereof,
wherein the degradation of solifenacin or a salt thereof is
inhibited over time and the mixture essentially contains
amorphous solifenacin or an amorphous salt thereof with an
amorphous content within a range with no influence on product
stability.
As to the amount of solifenacin or a salt thereof to be
blended in the composition for use in solid formulation in
accordance with the invention, the composition satisfactorily
contains an active amount of solifenacin or a salt thereof per

unit dose formulation.
The method for producing the "composition of solifenacin
or a salt thereof for use in solid formulation, the composition
containing crystalline solifenacin or a crystalline salt
thereof, wherein the amorphous content of solifenacin or a salt
thereof is within a range with no influence on product
stability" is any of a method with no use of any solvent to
prepare solifenacin or a salt thereof into an amorphous state,
or a method including a step of reducing the contact of
solifenacin or a salt thereof with a solvent in the course of
dissolving solifenacin or a salt thereof in the solvent to
prepare solifenacin or a salt thereof into an amorphous state
to generate the amorphous substance, wherein the amorphous
content is within a range with no influence on product stability,
or a method including a step of heating and/or moisturizing
a composition with an amorphous content over the range with
no influence on product stability during the production or
after the production, to adjust the amorphous content within
a range with no influence on product stability, with no specific
limitation to either the apparatus or the means.
As the production conditions to adjust the amorphous
content of solifenacin or a salt thereof within a range with
no influence on product stability, various production
conditions can be suggested. Specifically, one of the
production conditions is characteristically a production

process with no use of any solvent to prepare solifenacin or
a salt thereof into an amorphous state. For the phrase
"production process with no use of any solvent to prepare
solifenacin or a salt thereof into an amorphous state", a
production process by direct tableting is included, which
comprises mixing solifenacin or a salt thereof with an
appropriate excipients with no use of any solvent and compress
molding the resulting mixture if necessary to obtain a tablet.
In case that the method includes a step of adding a solvent,
the method includes using a solvent hardly preparing
solifenacin or a salt thereof into an amorphous state, wherein
the amount of solifenacin or a salt thereof to be dissolved
in 1 mL of the solvent is less than 0.1 mg, for example acetone,
hexane or a mixture thereof, for wet granulation.
In case of a manufacturing process to prepare solifenacin
or a salt thereof into an amorphous state, in a manufacturing
step of adding a solvent preparing solifenacin or a salt thereof
into an amorphous state, a stable composition of solifenacin
or a salt thereof for use in solid formulation can be produced
under manufacturing conditions for reducing the amount and
addition rate of solvents added, such as water to be used in
the manufacturing step and under production conditions for
securely achieving the intended quality of the resulting
granule, to adjust the amorphous content within a range with
no influence on product stability. The solvent to prepare

solifenacin or a salt thereof into an amorphous state as
referred to herein means a solvent wherein the amount of
solifenacin or a salt thereof to be dissolved in 1 mL of the
solvent is 10 mg or more, for example, water, methanol or
ethanol or mixtures thereof, which is more preferably wat-er.
Specifically, in a step of spraying an aqueous solution
dissolved therein as a binder solution on a powder containing
solifenacin or a salt thereof in producing the composition for
use in solid formulation, the product is satisfactorily
manufactured by preparing a granule with a moisture content
adjusted to a given value or less during the spraying of the
binder solution. The moisture content in the granule during
or after the spraying of a binder solution is adjusted to
preferably 9 % or less, more preferably 6 % or less,
particularly preferably 5 % or less, most preferably 4 % or
less.
Even when a composition at an amorphous content of
solifenacin or a salt thereof being 77 % or more is produced
not by the manufacturing method described above but by the
general wet granulation method, the crystallization process
of the composition is promoted to obtaiin a composition at an
amorphous content of solifenacin or a salt thereof within a
range with no influence on product stability. The promotion
of the crystallization process as referred to herein may be
done by any manufacturing process of promoting the

crystallization of amorphous solifenacin or a salt thereof,
with no specific limitation. The manufacturing process
includes for example heating and/or moisturizing process,
microwave irradiation process, low-frequency irradiation
process, ultrasonic irradiation process, and thermoelectron
irradiation process. The heating and/or moisturizing process
includes a manufacturing process of leaving the substance to
stand alone in a thermostat at a constant humidity, for example
under conditions of 25°C and 75 % RH for one week for subsequent
re-drying. Any manufacturing process of heating and/or
moisturizing the composition uniformly may be satisfactory,
with no specific limitation to the apparatus and the means.
For the microwave irradiation process, for example a
wavelength of 10 MHz to 25 GHz may be used. Additionally, the
processing time depends on the initial crystallization degree
and the selected substrate. The wavelength described above
is used for irradiation for example for 10 seconds to 60 minutes.
Irradiation may be done continuously or intermittently. The
timing for these crystallization-promoting processes may be
any timing when a stable composition of solifenacin or a salt
thereof for use in solid formulation can be obtained, with no
specific limitation. Manufacturing a granule of solifenacin
or a salt thereof or after producing a composition for use in
solid formulation.
The manufacturing process includes for example a direct

tableting process of mixing solifenacin or a salt thereof with
an appropriate additive and compress molding the mixture if
necessary to obtain a tablet, a wet granulation process of
mixing solifenacin or a salt thereof with an appropriate
additive and then spraying a binder solution on the resulting
mixture to prepare a granule, and a melt granulation process
of mixing solifenacin or a salt thereof with an appropriate
substance with a low melting point and heating and granulating
the mixture. Since solifenacin or a salt thereof has strong
aggregation property so it is difficult to securely keep the
content uniformity and the mixture sticks to punches during
compression by the direct tableting process, and it is very
difficult to control the amount of a substance with a low
melting point to be dissolved by the melt granulation process,
the wet granulation process is preferable as the manufacturing
process in accordance with the invention.
The wet granulation process includes for example a
process of pulverizing solifenacin or a salt thereof with a
pulverizing machine, subsequently mixing the resulting powder
with a pharmaceutically acceptable additive such as excipients
and disintegrators, spraying a binder solution on the mixture
to prepare a granule, mixing a lubricant into the granule, and
compressing the mixtures into a tablet. According to the
process, it is understood that crystalline solifenacin or a
crystal salt thereof is dissolved in the sprayed binder

solution at the step of spraying the binder solution for
granulation and then drying the resulting granule, to generate
the amorphous product. By reducing the spray rate of the
binder solution during granulation, reducing the total amount
of the binder solution, or raising the temperature of charged
air or the like to reduce the dissolution of solifenacin or
a salt thereof in the binder solution to consequently reduce
the generated amorphous form, a pharmaceutical composition for
use in solid formulation can be supplied.
The preferable spray rate of a binder solution, depending
on the manufacturing process or the manufacturing scale. The
spray rate is preferably 40 to 100 g/min, more preferably 50
to 80 g/min when manufactured at a 5-kg scale by a fluidized
bed granulation process. The preferable total amount of a
binder solution, depending on the manufacturing process or the
manufacturing scale. For production at a 5-kg scale by the
fluidized bed process, the total amount thereof is preferably
1000 kg to 2500 kg, more preferably 1500 kg to 2200 kg. The
preferable charged air temperature varies depending on the
production process or the production scale. For production
at a 5-kg scale by the fluidized bed process, however, the
temperature is preferably 50 to 80°C, more preferably 60 to
80°C.
The pulverizing machine includes for example hammer mill,
ball mill, jet mill and colloid mill. Generally, any process

capable of pharmaceutical pulverization may be satisfactory,
with no specific limitation to the apparatus or the means.
The blending apparatus of the individual components as
used continuously to pulverization includes for example Type
V mixer, ribbon-type mixer, container mixer, and high-speed
agitation. Generally, any process capable of
pharmaceutically uniformly mixing the individual components
may be satisfactory, with no specific limitation to the
apparatus or the means.
The granulation apparatus (process) includes for
example high-speed agitation granulation process, fluidized
bed granulation process, extrusion granulation process, and
rolling granulation process. Any granulation process using
a binder solution may be satisfactory, with no specific
limitation to the apparatus or the means.
The tableting apparatus includes for example rotary
tableting machine and single tableting machine. Generally,
any process capable of producing compress-molded products
(preferably, tablets) may be satisfactory, with no specific
limitation to the apparatus or the means.
The binder for use in the wet granulation process
includes for example hydroxypropylmethyl cellulose, and
polyvinylpyrrolidone. Generally, any binder with a
pharmaceutically acceptable powder-binding power may be
satisfactory, with no specific limitation.

Generally, the amount of such binder to be used may be
an amount thereof to give a pharmaceutically acceptable
granulation product, with no specific limitation. Generally,
the amount is 0.5 to 50 % by weight per unit dose, preferably
0.5 to 10 % by weight per unit dose, more preferably 2 to 5 %
by weight per unit dose.
For such pharmaceutical composition for use in solid
formulation in accordance with the invention, further, various
pharmaceutical excipients may appropriately be used for
formulation. Such pharmaceutical excipients may be any
pharmaceutically acceptable and pharmacologically acceptable
excipients, with no specific limitation. For example, binders,
disintegrators, sour agents, foaming agents, artificial
sweeteners, flavor, lubricants, coloring agents, stabilizers,
buffers, anti-oxidants, and surfactants may be used. For
example, the binders include hydroxypropylmethyl cellulose
and gum Arabic. The disintegrating agents include for example
corn starch, potato starch, calcium carmellose, and sodium
carmellose. The sour agents include for example citric acid,
tartaric acid and malic acid. The foaming agents include for
example sodium bicarbonate. The artificial sweeteners
include for example saccharine sodium, glycyrrhizin
dipotassium, aspartame, stevia, and somatin. The flavor
includes for example lemon, lemon lime,, orange and menthol.
The lubricants include for example magnesium stearate, calcium

stearate, sucrose fatty acid ester, polyethylene glycol, talc,
and stearic acid. The coloring agents include for example
yellow iron sesquioxide, red iron sesquioxide, Edible Yellow
Nos. 4 and 5, Edible Red Nos.3 and 102, and Edible Blue No.
3. The buffers include for example citric acid, succinic acid,
fumaric acid, tartaric acid, ascorbic acid or salts thereof,
glutamic acid, glutamine, glycine, aspartic acid, alanine,
arginine or salts thereof, magnesium oxide, zinc oxide,
magnesium hydroxide, phosphoric acid, boric acid or salts
thereof. The anti-oxidants include for example ascorbic acid,
dibutylhydroxytoluene, propyl gallate. The surfactants
include fore example polysorbate 80, sodium laurylsulfate, and
polyoxyethylene hardened castor oil. One type or two types
or more of such excipients may appropriately be added in
combination at an appropriate amount.
Further, the "inhibitor of amorphous preparation" means
a substance inhibiting the generation of amorphous solifenacin
or an amorphous salt thereof when solifenacin or a salt thereof
is dissolved in a solvent and then solidified by drying and
the like in preparing a composition of solifenacin or a salt
thereof for use in solid formulation, using a solvent.
The inhibitor of amorphous preparation is preferably a
substance with ethylene oxide chain. The substance with
ethylene oxide chain as herein referred to is any substance
with ethylene oxide chain with no specific limitation. As long

as the purpose of inhibiting the amorphous preparation of
solifenacin or a salt thereof in accordance with the invention
is achieved by adding a substance, the substance may be any
molecular species or have any molecular weight or any
polymerization degree, with no specific limitation. The
molecular weight is preferablV within an average molecular
range of 400 to 1,000,000, more preferably within an average
molecular range of 2,000 to 200,000. As the substance with
ethylene oxide chain, two or more types of the substance may
be used in mixture. In accordance with the invention,
specifically, the substance with ethylene oxide chain includes
for example PEG, polyethylene oxide, polyoxyethylene
polyoxypropylene block copolymer, polyoxyethylene hardened
castor oil (abbreviated as HCO hereinafter), and polyethylene
glycol fatty acid ester. Amorng them, in particular, PEG,
polyoxyethylene polyoxypropylene block copolymer or HCO is
preferable. PEG is more preferable.
The polyoxyethylene polyoxypropylene block copolymer in
accordance with the invention ma[y be a copolymer of propylene
oxide and ethylene oxide. Depending on the composition ratio,
various such copolymers exist. Any such copolymer with a
composition ratio with a property to inhibit amorphous
preparation of solifenacin or a salt thereof may be
satisfactory. Specifically, for example, polyoxyethylene
(105) polyoxypropylene (5) glycol and polyoxyethylene (160)

polyoxypropylene (30) glycol (Pluronic F68 under another name)
may be used.
The inhibitor of amorphous preparation is used at an
amount of preferably 0.1 to 90 % by weight, more preferably
1 to 60 % by weight to the total of the formulation. When PEG
is used as a binder for use in the wet granulation process by
dissolving PEG in distilled water, the amount is preferably
3 to 20 % by weight, more preferably 4 to 10 % by weight to
the powder to be granulated. When the amount of the inhibitor
of amorphous preparation is examined relatively to one part
by weight of crystalline and amorphous solifenacin or salt
thereof, the amount is preferably at a ratio of 0.001 to
100,000 % by weight, more preferably at a ratio of 1 to 1,000 %
by weight, still more preferably at a ratio of 10 to 600 % by
weight.
In accordance with the invention, the phrase
"containing" means that solifenacin or a salt thereof as the
active pharmaceutical ingredient is in mixture with the
inhibitor of amorphous preparation. Preferably, solifenacin
or a salt thereof is in contact with an inhibitor of amorphous
preparation so that solifenacin or a salt thereof is
distributed in a state of mixture. As in the case of using
a pharmaceutical composition as a coating agent of solifenacin
formulation wherein the active pharmaceutical ingredient,
solifenacin or a salt thereof, is not in contact with or in

mixture with such inhibitor of amorphous preparation so that
it exists in a localized state (for example the inhibitor of
amorphous preparation in accordance with the invention (PEG) ) ,
pharmaceutical preparations for example at a state such that
solifenacin or a salt thereof is not in physical contact with
a inhibitor of amorphous preparation in an intermediate layer
using other additives and the like are excluded.
A pharmaceutical composition of solifenacin or a salt thereof
for use in solid formulation in accordance with the invention
is now described in detail. In the following Examples and
Comparative Examples, the invention is described in more
detail. However, the invention is not construed in a limited
manner by them.
[Reference Example 1]
60 parts of solifenacin succinate were dissolved in 140
parts of water, for spray-drying with a spray dryer (DL-41,
manufactured by Yamato Science), to obtain a spray-dried
product.
The crystallinity of the resulting spray-dried product
of solifenacin succinate was measured by an X-ray diffraction
apparatus (RINT 1400 manufactured by Rigaku Denki) . A halo
pattern was observed, indicating the product was amorphous.

The results of the stability of the crystalline product,
before spray-drying, and amorphous product are shown in Table

1. The amounts of degradation products over time under storage
were measured by high-performance liquid chromatography. The
maximum amount of the individual degradation products is shown.
In a short period of time after the start of storage,
degradation products of amorphous solifenacin succinate
product were generated and the stability thereof was poorer
than that of the crystalline product. Therefore, the main
cause of the degradation of the active pharmaceutical
ingredient over time was presumably amorphous solifenacin
succinate generated in the manufacturing process of the
formulation.
Results of the stability of crystalline product and
amorphous product of solifenacin succinate
Storage conditions: 40°C and 75 % RH
Packaging form: glass vial
Test items: related substances (individual maximum values)

Example 1
204 parts of hydroxypropylmethyl cellulose 2910 was
dissolved and agitated in 1836 parts of water with an air motor
agitator (AM-GC-1, manufactured by Chuo-Rika Machine), to

prepare a binder solution (at a concentration of 10.0 W/V %) .
Then, 340 parts of solifenacin succinate and 1360 parts of
lactose were mixed together. Then, the resulting mixture was
pulverized with a hammer mill (sample mill AP-S using 1-mm
screen, manufactured by Hosokawa Micron). 2125 parts of
lactose and 1020 parts of corn starch were added to the mixed
and pulverized product and then were charged in a fluidized
bed granulation machine (WSG-5 manufactured by Powlec) for
spraying the binder solution at a charged air temperature of
65°C, an air flow volume of 4 M3/min, a spray rate of the binder
solution at 75 g/min, a spraying air pressure of 1.5 kg/cm2,
and a spray/shaking cycle of 30 seconds/10 seconds, for
granulation. The moisture content in the granule when sprayed
with the total volume of the binder solution was 3.9 %. After
granulation, the granule was dried at a charged air temperature
of 50°C for 10 minutes, to obtain the granule of the invention.
12 parts of magnesium stearate were added to 1188 parts of the
dried granulated product for mixing with a mixer (type DC
manufactured by Yamanouchi). Thereafter, the resulting
mixture was compressed with a rotary tableting machine (HT P-22
manufactured by Hata Tekkosho) with a 7.5 mm-φ punch at a
tableting pressure at about 700 kgf/punch to a tablet weight
of 150 mg. Further, 800 parts of the resulting tablet were
sprayed and coated with a solution prepared by
dissolving/dispersing 84.3 parts of hydroxypropylmethyl

cellulose, 15.8 parts of Macrogol 6000, 25.3 parts of talc,
10.5 parts of titanium oxide, and 0.03 part of red iron
sesquioxide in 1223 parts, using an aerated coating machine
(high coater HCT-30 manufactured by Freund Industry
Corporation) at a charged air temperature of 60°C, a pan
rotation velocity of 13 rpm, and a coating fluid feed rate of
5 g/min to a 2.7-% ratio of the coating agent to the tablet
weight, to obtain the film-coated tablet of the invention.
Example 2
Granulation was done by spraying the binder solution
under granulation conditions with a fluidized bed granulation
machine such that the charged air temperature was 65°C; the
air flow volume was 4 mVmin; the binder solution spray rate
was 75 g/min; the spray air pressure was 0.7 kg/cm2; and the
cycle of spray/shaking was 30 seconds/10 seconds. The
moisture content in the granule was 5.5 % when the total volume
of the binder solution was sprayed. After granulation, the
film-coated tablet of the invention was prepared by the method
described in Example 1.
Example 3
Granulation was done by spraying the binder solution
under granulation conditions with a fluidized bed granulation
machine such that the charged air temperature was 65°C; the

air flow volume was 4 mVmin; the binder solution spray rate
was 95 g/min; the spray air pressure was 1.5 kg/cm2; and the
cycle of spray/shaking was 30 seconds/10 seconds. The
moisture content in the granule was 5.7 % when the total volume
of the binder solution was sprayed. After granulation, the
film-coated tablet of the invention was prepared by the method
described in Example 1.
Example 4
Granulation was done by spraying the binder solution
under granulation conditions with a f luidized bed granulation
machine such that the charged air temperature was 55°C; the
air flow volume was 4 mVmin; the binder solution spray rate
was 75 g/min; the spray air pressure was 1.5 kg/cm2; and the
cycle of spray/shaking was 30 seconds/10 seconds. The
moisture content in the granule was 8.4 % when the total volume
of the binder solution was sprayed. After granulation, the
film-coated tablet of the invention was prepared by the method
described in Example 1.
[Comparative Example 1]
Granulation was done by spraying the binder solution
under granulation conditions with a f luidized bed granulation
machine such that the charged air temperature was 65°C; the
air flow volume was 4 mVmin; the binder solution spray rate

was 115 g/min; the spray air pressure was 1.5 kg/cm2; and the
cycle of spray/shaking was 30 seconds/10 seconds. The
moisture content in the granule was 10. 6 % when the total volume
of the binder solution was sprayed. After granulation, the
film-coated tablet of the invention was prepared by the method
described in Example 1.
[Comparative Example 2]
Granulation was done by spraying the binder solution
under granulation conditions with a fluidized bed granulation
machine such that the charged air temperature was 65°C; the
air flow volume was 3 mVmin; the binder solution spray rate
was 75 g/min; the spray air pressure was 1.5 kg/cm2; and the
cycle of spray/shaking was 30 seconds/10 seconds. The
moisture content in the granule was 10.6 % when the total volume
of the binder solution was sprayed. After granulation, the
film-coated tablet of the invention was prepared by the method
described in Example 1.
[Comparative Example 3]
Granulation was done by spraying the binder solution
under granulation conditions with a fluidized bed granulation
machine such that the charged air temperature was 45°C; the
air flow volume was 4 mVmin; the binder solution spray rate
was 75 g/min; the spray air pressure was 1.5 kg/cm2; and the

cycle of spray/shaking was 30 seconds/10 seconds. The
moisture content in the granule was 10.8 % when the total volume
of the binder solution was sprayed. After granulation, the
film-coated tablet of the invention was prepared by the method
described in Example 1.

The results of the moisture content of granule after
spraying the binder solution, the content of amorphous
solifenacin succinate and the preliminary stability using
bottle-sealing conditions at 40QC in 75 % RH for 6 months are
shown in Table 2 when manufacturing conditions were modified
during granulation. The moisture content of granule after
spraying the binder solution is shown as the value measured
by loss on drying method (80°C, 2 hours), while the content
of amorphous solifenacin succinate is shown as the value
measured by near infrared spectrometry. The near infrared
spectrometry was done by measuring the spectrum by Fourier
Transform near infrared spectrometer (Vector 22/N, Bruker
Optik GmbH, Germany) (measured range of 10000 cm"1 to 4000 cm"1,
resolution; 2 cm-1, scan number; 126) . The resulting spectrum
was secondarily derivative (Savitzky-Gollay convolution
method) and analyzed with a near infrared spectrum analysis

software (OPUS, Bruker Optik GmbH, Germany) . Before measuring
the spectrum of the tablet, the spectra of products prepared
by mixing crystalline and amorphous solifenacin succinate
preliminarily prepared by spray-drying an aqueous solifenacin
succinate solution at various ratios were subjected to
regression analysis by partial least squares method to prepare
a standard curve. The spectrum of the tablet was inserted on
the standard curve to determine the amount of amorphous
solifenacin succinate. Additionally, the amounts of
degradation products after storage for 6 months using
bottle-sealing conditions at 40°C in 75 % RH were measured by
high-performance liquid chromatography. Among the amounts of
degradation products as thus determined, the amount of the main
degradation product (F1) generated to the total amount of
solifenacin succinate and degradation products thereof is
shown. Using the ratio of the generated Fl as an indicator,
the stability of solifenacin succinate was examined.
Moisture content of granule during granulation in 10-mg
tablet of solifenacin succinate, the content of amorphous
solifenacin succinate in the tablet and the preliminary test
of the stability (for 6 months)


As shown in Table 2, the 10-mg tablets prepared under
the individual manufacturing conditions have different
moisture contents during granulations. As the moisture
contents in the granules were lower, generally, the amorphous
contents in the tablets were lower.
In Comparative Examples 1 through 3 as general
manufacturing processes, the moisture contents in the granules
after spraying binder solutions were larger than in the
Examples. Therefore, the amorphous solifenacin contents were
as large as 90 % or more. Additionally, the amount of the main
degradation product F1 to the total of solifenacin succinate
and degradation products thereof exceeds 0.4 %. This
indicates that a serious problem exists in providing a
composition of solifenacin or a salt thereof being stable over
time to clinical practice.
In case of controlling the moisture content in the
granule as less as possible as in Examples 1 through 4,
alternatively, the amorphous contents under controls of

moisture content were 77 % or less, while the amount of the
main degradation product F1 to the total of solifenacin
succinate and degradation products thereof was 0.4 % or less.
Thus, a solifenacin formulation stable over time can be
provided by controlling the amorphous content to 77 % or less
in a formulation containing solifenacin or a salt thereof.
Example 5
270 parts of PEG (Macrogol 6000 under trade name,
manufactured by Sanyo Chemical) were dissolved and agitated
in 1080 parts of water with an air motor agitator (AM-GC-1,
manufactured by Chuo Rika) to prepare a binder solution (at
a concentration of 20.0 W/V %) . Then, 90 parts of solifenacin
succinate and 360 parts of lactose (Lactose 200M under trade
name, manufactured by DMV) were mixed together. Then, the
resulting mixture was pulverized with a hammer mill (sample
mill AP-S, using 1-MM screen, manufactured by Hosokawa Micron) .
3906 parts of lactose and crystalline cellulose (Avicel PH 102
under trade name, manufactured by Asahi Chemical) were added
to the mixed and pulverized product and then were charged in
a fluidized bed granulation machine (WSG-5 manufactured by
Powlec) for spraying the binder solution at a charged air
temperature of 70°C, a spray rate of the binder solution at
100 g/min, a spraying air pressure of 1.5 kg/cm2, and a
spray/shaking cycle of 30 seconds/10 seconds, for granulation.

After granulation, the granule was dried at a charged air
temperature of 70°C for 10 minutes, to obtain the granule of
the invention. 12 parts of magnesium stearate (manufactured
by NOF) were added to 1188 parts of the dried granulated product
for blending with a mixer (type DC manufactured by Yamanouchi) .
Thereafter, the resulting mixture was compressed with a rotary
tableting machine (HT P-22 manufactured by Hata Tekkosho) with
a 5.5 mm-φ punch at a compression pressure of about 500
kgf/punch to a tablet weight of 60 mg. Further, 900 parts of
the resulting tablet were sprayed and coated with a solution
prepared by dissolving/dispersing 18.6 parts of HPMC 2910
(TC-5R under trade name, manufactured by Shin-estu Chemical) ,
3.5 parts of PEG (Macrogol 6000 under trade name, manufactured
by Sanyo Chemical) , 5.6 parts of talc (manufactured by Kihara
Chemical) ,2.3 parts of titanium oxide (manufactured by Freund
Industry Corporation), and 0-05 part of red iron sesquioxide
in 270 parts of water, using an aerated coating machine (high
coater HCT-30 manufactured by Freund Industry Corporation) at
a charged air temperature of 60°C, a pan rotation velocity of
13 rpm, and coating fluid feed rate of 5 g/min to a 3.3-% ratio
of the coating component to the tablet weight, to obtain the
film-coated tablet of the invention.
[Comparative Example 4]
180 parts of HPMC 2910 (TC-5R under trade name,

manufactured by Shin-estu chemical) were dissolved and
agitated in 1620 parts of water with an air motor agitator
(AM-GC-1, manufactured by Chuo Rika) to prepare a binder
solution (at a concentration of 10.0 W/V %) . Then, 75 parts
of solifenacin succinate and 300 parts of lactose were mixed
together. Then, the resulting mixture was pulverized with a
hammer mill (sample mill AP-S, using 1-mm screen, manufactured
by Hosokawa Micron). 2700 parts of lactose and 900 parts of
corn starch (manufactured by Nihon Shokuhin) were added to the
mixed and pulverized product and then were charged in a
fluidized bed granulation machine (WSG-5 manufactured by
Powlec) for spraying the binder solution at a charged air
temperature of 60°C, a spray rate of the binder solution at
75 g/min, a spraying air pressure of 1.5 kg/cm2, and a
spray/shaking cycle of 30 seconds/10 seconds, for granulation.
After granulation, the granule was dried at a charged air
temperature of 60°C for 10 minutes, to obtain the granule of
the invention. 12 parts of magnesium stearate (manufactured
by NOF) were added to 1188 parts of the dried granule for
blending with a mixer (type DC manufactured by Yamanouchi).
Thereafter, the resulting mixture was compressed with a rotary
tableting machine (HT P-22 manufactured by Hata Tekkosho) with
a 5.5 mm-φ punch at a compression pressure of about 500
kgf/punch to a tablet weight of 60 mg. Further, 900 parts of
the resulting tablet were coated by the process shown in Example

5, to obtain the film-coated tablet of the invention.
[Comparative Example 5]
108 parts of corn starch (manufactured by Nihon Shokuhin)
were added to 2592 parts of water and then dissolved therein
under heating to 80°C. Then, the resulting solution was cooled
to ambient temperature, to prepare a binder solution. Then,
90 parts of solifenacin succinate and 360 parts of lactose were
mixed together. Then, the resulting mixture was pulverized
with a hammer mill (sample mill AP-S, using 1-mm screen,
manufactured by Hosokawa Micron). 3708 parts of lactose and
1080 parts of corn starch were added to the mixed and pulverized
product and then were charged in a fluidized bed granulation
machine (WSG-5 manufactured by Powlec) for spraying the binder
solution at a charged air temperature of 70°C, a spray rate
of the binder solution at 90 g/min, a spraying air pressure
of 1.5 kg/cm2, and a spray/shaking cycle of 30 seconds/10
seconds, for granulation. After granulation, the granule was
dried at a charged air temperature of 70°C for 10 minutes, to
obtain the granule of the invention. 13 parts of magnesium
stearate were added to 129 parts of the dried granulated product
for blending with a mixer (type DC manufactured by Yamanouchi) .
Thereafter, the resulting mixture was compressed with a rotary
tableting machine (HT P-22 manufactured by Hata Tekkosho) with
a 5.5 mm-φ punch at a compression pressure of about 500

kgf/punch to a tablet weight of 60 mg. Further, 800 parts of
the resulting tablet were sprayed and coated by the process
shown in Example 5, to obtain the film-coated tablet of the
invention.

A preliminary stability test of a solifenacin succinate
tablet manufactured with a binder solution different from
those used in the granulation was done (under conditions of
25°C and 60 % RH) . The results are shown in Table 3.
The table of Comparative Example 4 as produced using HPMC
could not be stabilized sufficiently. Even when other binder
types were examined, starch could not improve the stability
as shown in Comparative Example 5. As shown in Example 5,
meanwhile, the use of PEG could improve the stability. It was
indicated that even under severer conditions of temperature
and humidity than the conditions of 25°C and 60 % RH, the
stability of solifenacin formulation could be retained.
Results of preliminary stability test of solifenacin succinate
tablet.
Storage conditions: 25°C and 60% RH
Packaging form: packed in metal-capped HDPE bottle
Test items: related substances (amount of main degradation
product F1 generated)


Industrial Applicability
The technical feature of the invention resides in the
elucidation of the cause of the degradation of the active
pharmaceutical ingredient in a formulation containing
solifenacin or a salt thereof over time, which was amorphous
solifenacin or an amorphous salt thereof. By preparing such
formulation by adjusting the amorphous content therein to a
given value or less, a stable solid formulation of solifenacin
or a salt thereof could first be provided, which was an
industrially great advantage. In a formulation containing
solifenacin or a salt thereof, additionally, an inhibitor of
amorphous preparation was contained therein, to enable the
provision of a stable pharmaceutical composition for use in
solid, which was an industrially great advantage.
Thus, the invention is useful as a technique enabling
the provision of a stable composition of solifenacin or a salt
thereof for use in solid formulation, of which the development
as a pharmaceutical product for pollakiuria and incontinence
of urine has been strongly desired.

We Claim:
1. A pharmaceutical composition for use in solid formulation, the
composition containing crystalline and amorphous solifenacin or a
crystalline and amorphous salt thereof, together with an inhibitor
of amorphous preparation.
2. A pharmaceutical composition as claimed in claim 10, wherein the
inhibitor of amorphous preparation is a substance having ethylene
oxide chain.
3. A pharmaceutical composition as claimed in claim 2, wherein the
substance with ethylene oxide chain is polyethylene glycol.

A pharmaceutical composition for use in solid formulation, the composition containing crystalline and amorphous solifenacin or a crystalline and amorphous salt thereof, together with an inhibitor of amorphous preparation.